A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...